23:05 , Aug 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2018. Therapeutic targets are defined as any protein, gene or other molecule...
17:18 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

FDA committee: 60 Degrees' malaria candidate safe and effective

FDA's Antimicrobial Drugs Advisory Committee voted that malaria candidate Arakoda tafenoquine (60P003) from 60 Degrees Pharmaceuticals LLC (Washington, D.C.) is effective and safe. The panel voted 11-2 that tafenoquine was effective in preventing malaria infection in...
15:27 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

FDA approves GSK's Krintafel to prevent malaria relapse

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Medicines for Malaria Venture (MMV) said FDA approved single-dose Krintafel tafenoquine to prevent relapse of Plasmodium vivax malaria in patients ages 16 and older who are receiving antimalarial therapy for...
20:59 , Jul 26, 2018 |  BC Extra  |  Company News

FDA committee: 60 Degrees' malaria candidate safe and effective

FDA's Antimicrobial Drugs Advisory Committee voted that malaria candidate tafenoquine (60P003) from 60 Degrees Pharmaceuticals LLC (Washington, D.C.) is effective and safe. The panel voted 11-2 that tafenoquine was effective in preventing malaria infection in adults...
19:05 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Malaria Mouse studies suggest an RNA-based vaccine encoding Plasmodium MIF could help prevent malaria infection. The vaccine consists of a lipid nanoparticle (LNP) loaded with Plasmodium MIF encoded by an alphaviral RNA replicon. In mouse...
23:51 , Jul 20, 2018 |  BC Extra  |  Company News

FDA approves Krintafel to prevent malaria relapse

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Medicines for Malaria Venture (MMV) said FDA approved single-dose Krintafel tafenoquine to prevent relapse of Plasmodium vivax malaria in patients ages 16 and older who are receiving antimalarial therapy for...
18:53 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

FDA panel votes in favor of GSK's malaria candidate

FDA's Antimicrobial Drugs Advisory Committee voted 13-0 that there is substantial evidence of the effectiveness of tafenoquine from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to prevent relapse of Plasmodium vivax malaria in patients 16 and older, and...
21:43 , Jul 12, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2018

New Therapeutic Targets and Biomarkers: June 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2018. Therapeutic targets are defined as any protein, gene or other molecule...
21:37 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Malaria Mouse studies suggest IL-33 or inhibiting NLRP3 could help treat cerebral malaria. In a mouse model of Plasmodium berghei-induced cerebral malaria treated with artesunate and chloroquine, brain levels of IL-33 were lower and brain...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...